954 F.Supp. 469 (D.Conn. 1996), 3 95CV01342, Glaxo Inc. v. Boehringer Ingelheim Corp.
Linked as:
Extract
954 F.Supp. 469 (D.Conn. 1996), 3 95CV01342, Glaxo Inc. v. Boehringer Ingelheim Corp.
No longer available (Autolink)
See the full content of this document
This document cites
- Federal Cases - 931 F.Supp. 1280 (E.D.N.C. 1996), 5 94-CV-527-BO 1, Glaxo Inc. v. Novopharm Ltd.
- Federal Cases - 69 F.3d 1130 (Fed. Cir. 1995), 95-1502, Bristol-Myers Squibb Co. v. Royce Laboratories, Inc.
- Federal Cases - 496 U.S. 661 (1990), 89-243, Eli Lilly and Company v. Medtronic, Inc.
- Federal Cases - 516 U.S. 1068 (1996), 95-5913, Brown v. United States
- US Code - 35 U.S.C. § 156 Extension of Patent Term
